FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507207148> ?p ?o ?g. }

• W2507207148 endingPage "2061" @default.
• W2507207148 startingPage "2061" @default.
• W2507207148 abstract "<ns4:p><ns4:bold>Objectives: </ns4:bold>To assess the uptake of pegylated interferon (PegIFN) plus ribavirin (RBV)-based regimens in patients with hepatitis C virus (HCV) in a large, single-centre, real-world setting over 10 years.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>This was a single centre, retrospective analysis of data from patients who attended their first appointment for treatment of HCV genotype 1–3 between 2003 and 2013. Patients were stratified by HCV genotype. The total number of patients who attended their first appointment, incidence of patients who did not proceed to treatment and associated reasons, and incidence of patients treated were analysed. Sustained virological response (SVR) rates were also reported for all patient populations.</ns4:p><ns4:p> <ns4:bold>Results: </ns4:bold>Overall, 1,132 patients attended their first appointment; 47.8% were included in the genotype 1 group (genotype 1a: 22.2%, genotype 1b: 13.3%, genotype 1 other: 12.3%), 7.7% in the genotype 2 group and 44.5% in the genotype 3 group. A greater proportion of patients received treatment versus those who did not receive treatment (84.4% vs 15.6%, respectively). Reasons for declining treatment included: patient declined treatment with PegIFN plus RBV: 35.0%, medical contraindications: 20.3% and mental health-related contraindications: 13.6%. An SVR was achieved in 52.6% of patients who attended their first appointment and 62.3% of patients who received treatment.</ns4:p><ns4:p> <ns4:bold>Conclusions: </ns4:bold>Approximately half of the patients included in this study achieved an SVR. A noteworthy proportion of patients did not receive treatment due to a reluctance to receive PegIFN plus RBV or contraindications to therapy. Results suggest an ongoing need for improvement in the treatment uptake and overall outcomes – particularly for genotype 2 and 3 patients for whom availability of interferon-free regimens is limited. The introduction of more tolerable direct-acting antiviral regimes may help overcome barriers to uptake demonstrated within this cohort.</ns4:p>" @default.
• W2507207148 created "2016-09-16" @default.
• W2507207148 creator A5061814401 @default.
• W2507207148 creator A5077276784 @default.
• W2507207148 date "2016-08-24" @default.
• W2507207148 modified "2023-10-17" @default.
• W2507207148 title "A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies" @default.
• W2507207148 cites W1482367278 @default.
• W2507207148 cites W1954432010 @default.
• W2507207148 cites W1961225815 @default.
• W2507207148 cites W1980771473 @default.
• W2507207148 cites W1987012521 @default.
• W2507207148 cites W2025524023 @default.
• W2507207148 cites W2027545702 @default.
• W2507207148 cites W2035625315 @default.
• W2507207148 cites W2039302135 @default.
• W2507207148 cites W2043193067 @default.
• W2507207148 cites W2050214831 @default.
• W2507207148 cites W2058828104 @default.
• W2507207148 cites W2071148746 @default.
• W2507207148 cites W2071958705 @default.
• W2507207148 cites W2079378191 @default.
• W2507207148 cites W2081897332 @default.
• W2507207148 cites W2084530058 @default.
• W2507207148 cites W2085764459 @default.
• W2507207148 cites W2088227275 @default.
• W2507207148 cites W2092646281 @default.
• W2507207148 cites W2096347191 @default.
• W2507207148 cites W2096808890 @default.
• W2507207148 cites W2107713887 @default.
• W2507207148 cites W2112876622 @default.
• W2507207148 cites W2125065061 @default.
• W2507207148 cites W2127685726 @default.
• W2507207148 cites W2131228788 @default.
• W2507207148 cites W2146956830 @default.
• W2507207148 cites W2150652264 @default.
• W2507207148 cites W2151554611 @default.
• W2507207148 cites W2159739349 @default.
• W2507207148 cites W2169503918 @default.
• W2507207148 cites W2170706646 @default.
• W2507207148 cites W2289667014 @default.
• W2507207148 cites W2325297898 @default.
• W2507207148 cites W2413303725 @default.
• W2507207148 cites W4230232450 @default.
• W2507207148 cites W4241616429 @default.
• W2507207148 cites W4292528167 @default.
• W2507207148 doi "https://doi.org/10.12688/f1000research.9114.1" @default.
• W2507207148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5034792" @default.
• W2507207148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27746906" @default.
• W2507207148 hasPublicationYear "2016" @default.
• W2507207148 type Work @default.
• W2507207148 sameAs 2507207148 @default.
• W2507207148 citedByCount "0" @default.
• W2507207148 crossrefType "journal-article" @default.
• W2507207148 hasAuthorship W2507207148A5061814401 @default.
• W2507207148 hasAuthorship W2507207148A5077276784 @default.
• W2507207148 hasBestOaLocation W25072071481 @default.
• W2507207148 hasConcept C104317684 @default.
• W2507207148 hasConcept C120665830 @default.
• W2507207148 hasConcept C121332964 @default.
• W2507207148 hasConcept C126322002 @default.
• W2507207148 hasConcept C135763542 @default.
• W2507207148 hasConcept C159047783 @default.
• W2507207148 hasConcept C2522874641 @default.
• W2507207148 hasConcept C2776408679 @default.
• W2507207148 hasConcept C2776461080 @default.
• W2507207148 hasConcept C2780040827 @default.
• W2507207148 hasConcept C55493867 @default.
• W2507207148 hasConcept C61511704 @default.
• W2507207148 hasConcept C71924100 @default.
• W2507207148 hasConcept C86803240 @default.
• W2507207148 hasConceptScore W2507207148C104317684 @default.
• W2507207148 hasConceptScore W2507207148C120665830 @default.
• W2507207148 hasConceptScore W2507207148C121332964 @default.
• W2507207148 hasConceptScore W2507207148C126322002 @default.
• W2507207148 hasConceptScore W2507207148C135763542 @default.
• W2507207148 hasConceptScore W2507207148C159047783 @default.
• W2507207148 hasConceptScore W2507207148C2522874641 @default.
• W2507207148 hasConceptScore W2507207148C2776408679 @default.
• W2507207148 hasConceptScore W2507207148C2776461080 @default.
• W2507207148 hasConceptScore W2507207148C2780040827 @default.
• W2507207148 hasConceptScore W2507207148C55493867 @default.
• W2507207148 hasConceptScore W2507207148C61511704 @default.
• W2507207148 hasConceptScore W2507207148C71924100 @default.
• W2507207148 hasConceptScore W2507207148C86803240 @default.
• W2507207148 hasLocation W25072071481 @default.
• W2507207148 hasLocation W25072071482 @default.
• W2507207148 hasLocation W25072071483 @default.
• W2507207148 hasLocation W25072071484 @default.
• W2507207148 hasOpenAccess W2507207148 @default.
• W2507207148 hasPrimaryLocation W25072071481 @default.
• W2507207148 hasRelatedWork W1481102184 @default.
• W2507207148 hasRelatedWork W1598582479 @default.
• W2507207148 hasRelatedWork W1976745213 @default.
• W2507207148 hasRelatedWork W1981089481 @default.
• W2507207148 hasRelatedWork W2006840037 @default.
• W2507207148 hasRelatedWork W2024493120 @default.
• W2507207148 hasRelatedWork W2047936743 @default.

• next